Suppr超能文献

组织蛋白酶B和癌胚抗原在结直肠癌患者血清中的预后价值。

Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer.

作者信息

Kos J, Nielsen H J, Krasovec M, Christensen I J, Cimerman N, Stephens R W, Brünner N

机构信息

Department of Biochemistry and Molecular Biology, Jozef Stefan Institute, Ljubljana, Slovenia.

出版信息

Clin Cancer Res. 1998 Jun;4(6):1511-6.

PMID:9626470
Abstract

The level of cathepsin B (Cat B) was determined in sera obtained preoperatively from 325 patients with colorectal cancer using an ELISA. Control sera from 90 healthy blood donors were analyzed. The levels of Cat B detected included all forms that were present in the sera, i.e., mature enzyme, precursor molecule, and enzyme-inhibitor complexes. The level of Cat B was significantly increased in sera of patients with colorectal cancer. The median level was 10.7 ng/ml versus 2.1 ng/ml in controls (P < 0.0001). A correlation between Cat B serum level and advanced Dukes' stage (P < 0.003) was found, whereas no associations have been found with age, sex, or level of carcinoembryonic antigen (CEA). In survival analysis, the patients with high serum Cat B experienced significantly lower survival probability. At the optimal cutoff value of 9.4 ng/ml, the relative hazard ratio was 1.8 (95% confidence interval, 1.1-2.8; P = 0.016) in the univariate Cox proportional hazards model. The median observation time was 4.4 years (range, 3.2-5.5 years). In multivariate analysis, Dukes' stage was the strongest prognostic variable, followed by age, whereas serum Cat B and CEA were not significant prognostic factors in this model, in accordance with their association with Dukes' stage. When the data for Cat B and CEA were combined, CEA-positive patients were further separated by Cat B into high- and low-risk groups. Patients with high serum levels of both molecules had significantly shorter survival (relative hazard ratio of 2.2; 95% confidence interval, 1.5-3.2; P < 0.0001), as compared with patients with low levels of both molecules.

摘要

采用酶联免疫吸附测定法(ELISA)检测了325例结直肠癌患者术前血清中的组织蛋白酶B(Cat B)水平。分析了90名健康献血者的对照血清。检测到的Cat B水平包括血清中存在的所有形式,即成熟酶、前体分子和酶-抑制剂复合物。结直肠癌患者血清中Cat B水平显著升高。中位数水平为10.7 ng/ml,而对照组为2.1 ng/ml(P<0.0001)。发现Cat B血清水平与Dukes分期进展相关(P<0.003),而未发现与年龄、性别或癌胚抗原(CEA)水平有关联。在生存分析中,血清Cat B水平高的患者生存概率显著较低。在单因素Cox比例风险模型中,最佳临界值为9.4 ng/ml时,相对风险比为1.8(95%置信区间,1.1 - 2.8;P = 0.016)。中位观察时间为4.4年(范围3.2 - 5.5年)。多因素分析中,Dukes分期是最强的预后变量,其次是年龄,而血清Cat B和CEA在该模型中不是显著的预后因素,这与它们与Dukes分期的关联一致。当将Cat B和CEA的数据合并时,CEA阳性患者根据Cat B进一步分为高风险和低风险组。与两种分子水平都低的患者相比,两种分子血清水平都高的患者生存时间显著缩短(相对风险比为2.2;95%置信区间,1.5 - 3.2;P<0.0001)。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验